VAXNEUVANCE susp inj 10 ser pré 0.5 ml
7680687520027
CH-68752
J07AL02
08.08.
Reimbursement limitations:
0808 NEU
La prise en charge des coûts des vaccins au titre de mesure préventive dans le …
1 / 3
google
Details
- Product number
- 6875201
- CPT
- -
- Packaging group
- 10
- Unit
- Fertigspritze(n)
- Composition
- polysaccharida streptococci pneumoniae typus 1 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 3 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 4 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 5 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 6A conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 6B conjugata cum proteino corynebacteriae diphtheriae CRM 197 4 µg et polysaccharida streptococci pneumoniae typus 7F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 9V conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 14 conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 18C conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 19A conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 19F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 22F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 23F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg et polysaccharida streptococci pneumoniae typus 33F conjugata cum proteino corynebacteriae diphtheriae CRM 197 2 µg corresp. polysaccharida 32 µg et proteinum corynebacteriae diphtheriae CRM 197 ca. 30 µg, adjuvans: aluminium 0.125 mg ut aluminii phosphas, natrii chloridum corresp. natrium 1.77 mg, histidinum, polysorbatum 20, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml.
Articles (1)
Vaxneuvance, Injektionssuspension
Injektionssuspension
10
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
4.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
2.0 UG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
32.0 UG | Substance | WIIS |
|
(N/A)
|
- | Substance | WIIS |
|
(N/A)
|
0.125 MG | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
1.77 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 650.25
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/05/2024
Authorization holder
MSD Merck Sharp & Dohme AG
6005 Luzern
Authorization information
- Swissmedic authorization number
- 68752
- Drug name
- Vaxneuvance, Injektionssuspension
- Galenic form
- INJFS
- ATC Code
- J07AL02
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 14/02/2023
- Authorization expiration date
- 13/02/2028
- IT number
- 08.08.
- Domain
- Human medicine
Packaging details
- Description (FR)
- VAXNEUVANCE sol inj 2 µg 10 pce
- Description (DE)
- VAXNEUVANCE Inj Lös 2 µg 10 Stk
- Market launch
- 14/02/2023
- Narcotic (BTM)
- No